Despite almost forty years of widespread use, the mode of action of antidepressant
drugs is still largely unknown. There is agreement that these drugs interact with
central neurotransmission. Common findings are acute inhibitory actions on reuptake
mechanisms for norepinephrine (NE) and for serotonin (5-HT) at presynaptic axons and
chronic adaptive effects on neurotransmitter receptors on postsynaptic membranes.
In particular, β-adrenoceptor downregulation has been observed after chronic treatment
with most antidepressants in vivo and in cell culture systems. We studied the effectiveness of Ze 117 (St. John's wort)
extract (Hypericum perforatum ) on NE- and 5-HT-uptake into rat brain slices. Potency and efficacy of the Ze 117
extract were compared with those of tricyclic (TCA) and selective serotonin reuptake
inhibitor (SSRI)-type antidepressants. A dose-dependent inhibition was seen on NE
and 5-HT uptake into brain slices. The Ze 117 extract was more selective for the uptake
of NE than for that of 5-HT. The maximal extent of uptake inhibition by Ze 117 extract
was comparable to that of imipramine (IMI), desipramine (DMI) or fluvoxamine for 5-HT,
but lower for NE transport, than that of the synthetic antidepressants. Chronic exposure
(8 days) of confluent C 6-cell cultures to Ze 117 extract resulted in a dose-dependent
β-adrenoceptor downregulation equal to that induced by DMI, a potent TCA. None of
these effects could be achieved with either hypericin or hyperforin alone in a relevant
dose range. Our results indicate that the St. John's wort extract Ze 117 contains
active, but as yet unknown antidepressant principles with effects comparable to those
of TCAs.
References
1
Baldessarini R J.
Current status of antidepressants: clinical pharmacology and therapy. J. Clin.
Psychiatry.
1989;
50
117-126
2
Banerjee S P, Kung L S, Riggi S J, Chanda S K.
Development of β-adrenergic receptor subsensitivity by antidepressants.
Nature.
1977;
268
455-456
3
Bolden-Watson C, Richelson E.
Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain
synaptosomes.
Life Sci.
1993;
52
1023-1029
4
Daniel W A, Bickel M H, Honegger U E.
The contribution of lysosomal trapping in the uptake of desipramine and chloroquine
by different tissues.
Pharmacol & Toxicol.
1995;
77
402-406
5
De Paermentier F, Cheetham S C, Crompton M R, Katona C L, Horton R W.
Brain β-adrenoceptor binding sites in depressed suicide victims effects of antidepressant
treatment.
Psychopharmacol.
1991;
105
283-288
6
Fishman P H, Finberg J.
Effect of the tricyclic antidepressant desipramine on β-adrenergic receptors in cultured
rat glioma C 6 cells.
J Neurochem.
1987;
49
282-289
7 Heninger G R, Charney D S.
Mechanisms of action of antidepressant treatments: implications for the etiology and
treatment of depressive disorders. In Meltzer, H.Y. (ed.) Psychopharmacology: The third generation of progress. New
York, Raven Press 1987: 535-544
8
Honegger U E, Disler B, Wiesmann U N.
Chronic exposure of human cells in culture to the tricyclic antidepressant desipramine
reduces the number of β-adrenoceptors.
Biochem Pharmacol.
1986;
35
1899-1902
9
Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D.
St. John's wort for depression - an overview and metaanalysis of randomised clinical
trials.
Brit Med J.
1996;
313
253-258
10
Manier D H, Bieck P R, Duhl D M, Gillespie D D, Sulser F.
The β-adrenoceptor-coupled adenylate cyclase system in rat C 6 glioma cells. Deamplification
by isoproterenol and oxaprotiline.
Neuropsychopharmacol.
1992;
7
105-112
11
Müller W E, Rolli M, Schäfer C, Hafner U.
Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.
Pharmacopsychiat.
1997;
30
(Suppl)
102-107
12
Müller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C.
Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum
extract.
Pharmacopsychiat.
1998;
31
(Suppl)
16-21
13
Neary J T, Bu Y.
Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes.
Brain Res.
1999;
816
358-363
14
Papp M, Nalepa I, Vetulani J.
Reversal by imipramine of β-adrenoceptor upregulation induced in a chronic mild stress
model of depression.
Eur J Pharmacol.
1994 ;
261
141-147
15
Schildkraut J J.
The catecholamine hypothesis of affective disorders: A review of supporting evidence.
Am J Psychiatry.
1965;
122
509-522
16
Schrader E.
Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled
study in mild - moderate depression.
Internat Clin Psychopharmacol.
2000;
15
61-68
17
Zemlan F P, Garver D L.
Depression and antidepressant therapy: receptor dynamics.
Prog Neuro-Psychopharmacol & Biol Psychiat.
1990;
14
503-523
Prof. Dr. Ulrich E. Honegger
Department of Pharmacology University of Bern
Friedbühlstraße 49
3010 Bern
Switzerland